When $80 million market cap QuadraMed Corp. publicized its review of strategic alternatives on July 27, the situation seemed to be an open-and-shut case.
To read the entire story, you must be logged in.
Please log in now or register with us.
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
